Search clinical trials for: Copanlisib (BAY80-6946)

Total 529 results

Bayer

Completed

Maintenance Treatment of Renal Anemia in Dialysis Subjects (MIYABI HD-M)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

Pilot Study to Assess Number of Patients for Main Trial

Wound Healing

Germany
Invicro

Completed

Phase 1 Evaluation of [18F]MK-6240 PET as an Imaging Marker for Tau Protein

Alzheimer Disease | Healthy Volunteers

United States
University of Michigan Rogel Cancer Center
Bristol-Myers Squibb; Bayer; University of Michigan; Big Ten Cancer Research Consortium

Active, not recruiting

Dose De-escalation Study of the PI3k Alpha/Delta Inhibitor, Copanlisib Given in Combination With the Immunotherapeutic Agents, Nivolumab and Rituximab in Patients With Relapsed/Refractory Indolent Lymphoma

Indolent Lymphoma

United States
Bayer

Completed

Drug Use Investigation (DUI) of YazFlex for Endometriosis-associated Pelvic Pain and/or Dysmenorrhea

Endometriosis and Dysmenorrhea

Japan
Bayer

Completed

A Phase 2/ 3 Trial to Evaluate the Efficacy and Safety of BAY86-6150

Hemophilia A, Hemophilia B

Italy, China, New Zealand, Russian Federation, Taiwan, Singapore, Bulgaria, United States, Denmark, Germany, Hungary, South Africa, United Kingdom, Romania, Colombia, Mexico, Turkey, France, India, Japan, Australia, Netherlands, Poland and more
Bayer

Completed

Liver MRI With Primovist/Eovist in Pediatric Subjects Who Are Suspected or Have Focal Liver Lesions.

Carcinoma | Liver Neoplasms | Adenoma | Liver Abscess

United States, Japan, Singapore, Taiwan, Italy
Bayer

Completed

Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function

Contraception

France, Italy, Spain, Germany, United Kingdom
Bayer

Completed

Primovist Regulatory Post Marketing Surveillance (PMS)

Liver

Korea, Republic of
Bayer

Completed

A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia

Menopause

Russian Federation
M.D. Anderson Cancer Center
Bayer

Active, not recruiting

Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations

Ovarian Cancer | Endometrial Cancer

United States
Bayer

Completed

A Study of Molidustat for Maintenance Treatment of Renal Anemia in Non-dialysis Subjects (MIYABI ND-M)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

Efficacy and Safety of Primovist in Chinese Patients

Known or Suspected Focal Liver Lesions

China
Bayer

Completed

Study on the Risk of Allergy-like Reactions After Intra-arterial or Intra-venous Injection of the Marketed X-ray Contrast Medium Iopromid (UVIA)

Contrast Medium

Germany
Bayer

Completed

YAZ Post-marketing Surveillance in Japan

Dysmenorrhea

Japan
Bayer

Completed

Efficacy and Safety Study of ZK219477 in Patients With Recurrent Ovarian Cancer

Ovarian Neoplasms
Bayer

Completed

The Safety and toleRability of UltraviSt in Patients Undergoing Cardiac CaTheterization (TRUST) (TRUST)

Angiocardiography

China
Bayer

Completed

Identification of Hepatic Lesions

Hepatic Neoplasms

Italy
Chonnam National University Hospital
Bayer; Consortium for Improving Survival of Lymphoma

Completed

Copanlisib and Gemcitabine in Relapsed/Refractory PTCL

Mature T-Cell and NK-Cell Neoplasm

Korea, Republic of
Bayer

Completed

A Non-interventional Study to Observe the Computed Tomographic Angiography Image Quality With Different Contrast Media Injection Protocols Under Different Computed Tomography Machines Parameters Setting (RIGHT)

Multidetector Computed Tomography | Angiography

China
Bayer

Completed

Observational Study of Ultravist in Patients Requiring CECT (INDEX)

Diagnostic Imaging

China
Bayer

Completed

Regulatory Post Marketing Surveillance Study on YAZ

Contraception | Acne | Premenstrual Syndrome

Korea, Republic of
Bayer

Completed

A Study of Molidustat for Correction of Renal Anemia in Dialysis Subjects (MIYABI HD-C)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Completed

Effects of Wellnara on Climacteric Symptoms

Postmenopause

Germany
Bayer

Completed

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Italy, Canada, Switzerland, Netherlands, United Kingdom, Portugal, Germany, Sweden, Denmark, Norway
Regeneron Pharmaceuticals
Bayer

Completed

Safety and Efficacy of Repeated Intravitreal Administration of Vascular Endothelial Growth Factor (VEGF) Trap in Patients With Wet Age-Related Macular Degeneration (AMD)

Macular Degeneration

United States
Bayer

Completed

A Study of Molidustat for Treatment of Renal Anemia in Peritoneal Dialysis Subjects (MIYABI PD)

Renal Insufficiency, Chronic | Anemia

Japan
Bayer

Terminated

Magnetic Resonance Imaging of the Liver in Children 0-2 Months of Age With an Intravenous Injection of Eovist/Primovist Which is a Contrast Agent

Magnetic Resonance Imaging

United States
Bayer

Completed

FC Patch Comparator Study

Contraception

France, Spain, Austria, Finland
Bayer

Terminated

Safety and Efficacy Study of a New Chemotherapy Agent to Treat Small Cell Lung Cancer

Small Cell Lung Carcinoma
Bayer

Completed

Fat Distribution in Healthy Early Postmenopausal Women

Healthy | Postmenopause

Austria
Bayer

Completed

Evaluation of the Positron Emission Tomography (PET) Tracer ZK 6032924 in Patients With Multiple Sclerosis Compared to Healthy Volunteers

Multiple Sclerosis | Positron-Emission Tomography

Australia, Sweden
Bayer

Completed

YAZ, Oral Contraceptive Registration in China

Contraception

China, Hong Kong
Bayer

Completed

Study to Investigate Efficacy and Safety of a New Oral Contraceptive

Contraception

Germany, Austria, Spain
Bayer

Completed

Comparative Study of BAY86-5300 With a Flexible Extended Regimen for Dysmenorrhea

Dysmenorrhea

Japan
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of the Anti-cancer Drugs Copanlisib, Olaparib, and MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumors With Selected Mutations

Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Active, not recruiting

Testing the Combination of Copanlisib, Nivolumab and Ipilimumab in Patients With Advanced Cancer and Lymphoma

Lymphoma | Unresectable Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm

United States
National Cancer Institute (NCI)

Terminated

Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer

Anatomic Stage IV Breast Cancer AJCC v8 | Metastatic Breast Carcinoma | HER2-Positive Breast Carcinoma

United States
Bayer

Completed

Qlaira Post-authorization Safety Study Related to Most Common Adverse Events in Mexican Women Who Wish to Avoid Pregnancy

Contraception

Mexico
Bayer

Completed

Efficacy and Safety of a Combined Oral Contraceptive of Estradiol Valerate and Dienogest in Healthy Female Subjects

Contraception

China, Taiwan, Thailand, India, Hong Kong
Bayer

Completed

Study on Safety and Efficacy of an Oral Contraceptive in Long Cycles

Contraception

Netherlands, Canada, Germany
Bayer

Withdrawn

Efficacy/Safety Study to Explore a New Topical Formulation in Atopic Dermatitis (Phoenix)

Dermatitis, Atopic

Germany
Bayer

Active, not recruiting

Drug Use Investigation of Kovaltry in Hemophilia A Patients

Hemophilia A

Japan
Bayer

Completed

BAY81-8973 Pediatric Safety and Efficacy Trial

Haemophilia A

Spain, Russian Federation, United States, Hungary, Italy, Mexico, Norway, Romania, Bulgaria, Canada, Argentina, Denmark, Israel, Poland, Ireland, Latvia, Lithuania
Bayer

Completed

YAZ Post Authorization Safety Study (PASS)/Post Authorization Efficacy Study (PAES) in China

Contraception

China
Bayer

Completed

Long Term Extension Study for the Maintenance Treatment of Anemia Associated With Chronic Kidney Disease (CKD) in Hemodialysis Subjects on Epoetin Alfa / Beta Treatment Versus BAY85-3934 (DIALOGUE5)

Renal Insufficiency, Chronic | Anemia

United States, Japan
Bayer

Withdrawn

To Investigate Efficacy of YAZ in the Treatment of Dysmenorrhea

Dysmenorrhea
Bayer

Completed

LCS12 vs Combined Oral Contraceptive (COC) User Satisfaction Study

Contraception

Belgium, United States, Russian Federation, Germany, Austria
Bayer
Regeneron Pharmaceuticals

Active, not recruiting

Study of the Effects of High Dose Aflibercept Injected Into the Eye of Patients With an Age-related Disorder That Causes Loss of Vision Due to Growth of Abnormal Blood Vessels at the Back of the Eye (PULSAR)

Neovascular Age-Related Macular Degeneration

United States, Spain, Korea, Republic of, Czechia, Japan, Singapore, China, Serbia, Lithuania, Taiwan, Australia, Estonia, Austria, Israel, France, Italy, Switzerland, Slovakia, Ukraine, Bulgaria, Portugal, Latvia, Canada, Hungary, Arge... and more
Bayer

Completed

Alpharadin™ (Radium-223 Chloride) Safety and Dosimetry With HRPC That Has Metastasized to the Skeleton

Prostate Cancer | Pharmacokinetics | Metastases

United States

3

Subscribe